Hazards of Recurrence, Second Primary, or Other Tumor at Ten Years After Surgery for Non-Small-Cell Lung Cancer.
Adenocarcinoma of Lung
/ pathology
Aged
Austria
/ epidemiology
Carcinoma, Non-Small-Cell Lung
/ pathology
Carcinoma, Squamous Cell
/ pathology
Female
Follow-Up Studies
Humans
Incidence
Lung Neoplasms
/ pathology
Male
Middle Aged
Neoplasm Recurrence, Local
/ epidemiology
Neoplasms, Second Primary
/ epidemiology
Pneumonectomy
/ adverse effects
Prognosis
Retrospective Studies
Survival Rate
Bronchial carcinoma
Long-term follow-up
Other malignancies
Prognosis
Relapse
Journal
Clinical lung cancer
ISSN: 1938-0690
Titre abrégé: Clin Lung Cancer
Pays: United States
ID NLM: 100893225
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
09
11
2019
revised:
29
01
2020
accepted:
13
02
2020
pubmed:
11
4
2020
medline:
6
7
2021
entrez:
11
4
2020
Statut:
ppublish
Résumé
Better treatment options entail the risk of multiple tumors in a patient's lifetime. We studied the incidence, risk factors, and prognostic impact of second primaries and other malignancies in patients with operated non-small-cell lung cancer (NSCLC). We retrospectively analyzed 342 consecutive patients with curatively resected NSCLC between 2003 and 2007. Among the 342 patients analyzed, 172 (50.3%) developed locoregional and/or distant recurrence; 25 (7.3%) had a second primary lung cancer, 97 (28.3%) had 1 or more malignancies other than NSCLC either in their history (n = 61; 17.8%) or following resection (n = 64; 18.7%). One hundred fifteen patients (33.6%) had a malignancy other than primary NSCLC. Eight patients developed both a second primary lung cancer and another malignancy. Older age and lower N-stage were significantly correlated with the occurrence of an additional tumor, as shown by a logistic regression nomogram. Whereas the risk of recurrence decreases over time, the risk of developing a second tumor, particularly a second primary lung cancer, remains high during up to 10 years of follow-up. One hundred seventy patients (49.7%) died of the primary (n = 158; 46.2%) or second primary (n = 12; 3.5%) NSCLC, 23 (6.7%) died of another malignancy, and 66 (19.3%) died due to unrelated causes (overall 10-year survival, 33.3%). Second primary lung cancer or other malignancy occurs in 33% of patients with NSCLC; 26% of patients are affected within 10 years after resection of lung cancer. With curative treatment of secondary tumors, there is no negative influence on long-term prognosis of NSCLC; therefore, follow-up beyond 5 years is strongly advisable.
Identifiants
pubmed: 32273257
pii: S1525-7304(20)30036-X
doi: 10.1016/j.cllc.2020.02.011
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-340Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.